The short version of clinical endpoint fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-28. Anything still debated is marked as such rather than presented as settled.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
The activity of this peptide is generally described as immunomodulatory rather than directly antimicrobial. Experimental work links it to signaling through certain Toll-like receptors on dendritic cells and to downstream maturation of antigen-presenting cells. Reported effects include expansion of T cell subsets, shifts in cytokine profiles, and increased natural killer cell activity. These observations come largely from cell culture and animal models, and the precise receptor-level events in humans remain incompletely characterized.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Lyophilized thymosin alpha-1 is generally stored at or below minus twenty degrees Celsius, protected from moisture and light. Short-term handling at ambient temperature is possible for dry powder, but reconstituted solutions degrade faster and are usually kept at two to eight degrees Celsius with a defined expiry of days rather than weeks. Repeated freeze-thaw cycles should be avoided because they promote aggregation and loss of potency. Exact limits depend on the formulation and should follow the supplier's documentation.
Identity and purity are normally assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and truncation products. Mass spectrometry confirms molecular mass and detects modifications such as deamidation or oxidation. Amino acid analysis and peptide mapping provide additional sequence-level confirmation. For research material, a certificate of analysis typically reports these results together with water content and counter-ion identity, since the lyophilized powder is often supplied as an acetate or trifluoroacetate salt.
While protein synthesis is globally regulated by modulating the expression of key initiation factors as well as the number of ribosomes, individual mRNAs can have different translation rates due to the presence of regulatory sequence elements. This has been shown to be important in a variety of settings including yeast meiosis and ethylene response in plants. In addition, recent work in yeast and humans suggest that evolutionary divergence in cis-regulatory sequences can impact translation regulation. Additionally, RNA helicases such as DHX29 and Ded1/DDX3 participate in the process of translation initiation, especially for mRNAs with structured 5'UTRs.
=== Alter ego === During her time on The Only Way Is Essex, Collins earned a reputation for being a diva. Her alter-ego was first created during the show's third series when her co-star Sam Faiers referred to Collins using her initials "The GC". Collins describes her alter-ego as an "intervention" and says she and The GC are "very different people". Speaking in 2020, she said "Although I'm Gemma Collins, I've got my brand the GC. Gemma Collins is a homely girl who loves watering hanging baskets. The GC, which is my brand, is basically a character that's over the top that people either love her or hate her, but on the back of her I've managed to launch perfumes and lipsticks." Collins embraces the term "diva" and says the word "empowers her". Her influences include Marilyn Monroe, Madonna, Beyoncé, Mariah Carey and Dolly Parton.
Houston producer DJ Screw popularized the concoction, which is widely attributed as a source of inspiration for the chopped-and-screwed style of hip hop music. The promethazine and codeine concoction first gained popularity in the underground hip hop scene in Houston, where musician Big Hawk said it was consumed as early as the 1960s and 1970s, becoming more widely used in the early 1990s. Because of usage by rap artists in Houston, it became more popular in the 1990s. Its use later spread to other States in the South. In June 2000, Three 6 Mafia's single "Sippin' on Some Syrup", featuring UGK, brought the term purple drank to a nationwide audience. In 2004, the University of Texas at Austin found that 8.3% of secondary school students in Texas had taken codeine syrup to get high. The Drug Enforcement Administration reports busts involving syrup across the Southern United States, particularly in Texas and Florida. As of 2011, the price of lean in Houston was twice the price it is in Los Angeles. In a 2019 interview, American rapper Future spoke about quitting lean and stated that he was afraid that his fans would believe his music has changed if he had publicly admitted to quitting earlier. Future expressed disappointment after American rapper Juice Wrld told him that he was influenced by his music to try lean when he was young. Future stated "It's like, 'Oh shit.' How many other sixth-graders did I influence to drink lean?" The two artists had released a collaborative mixtape titled Wrld on Drugs in October 2018.
Sources: en.wikipedia.org
=== Category:EC 2.8 (transfer sulfur-containing groups) === EC 2.8.1.1: Thiosulfate sulfurtransferase EC 2.8.1.2: 3-mercaptopyruvate sulfurtransferase EC 2.8.1.3: Thiosulfate—thiol sulfurtransferase EC 2.8.1.4: tRNA uracil 4-sulfurtransferase EC 2.8.1.5: Thiosulfate—dithiol sulfurtransferase EC 2.8.1.6: Biotin synthase EC 2.8.1.7: Cysteine desulfurase EC 2.8.1.8: Lipoyl synthase EC 2.8.1.9: Molybdenum cofactor sulfurtransferase EC 2.8.1.10: Thiazole synthase EC 2.8.1.11: Molybdopterin synthase sulfurtransferase EC 2.8.1.12: Molybdopterin synthase EC 2.8.1.13: tRNA-uridine 2-sulfurtransferase EC 2.8.1.14: tRNA-5-taurinomethyluridine 2-sulfurtransferase EC 2.8.1.15: tRNA-5-methyluridine(54) 2-sulfurtransferase
Formation of a secondary structure is the first step in the folding process that a protein takes to assume its native structure. Characteristic of secondary structure are the structures known as alpha helices and beta sheets that fold rapidly because they are stabilized by intramolecular hydrogen bonds, as was first characterized by Linus Pauling. Formation of intramolecular hydrogen bonds provides another important contribution to protein stability. α-helices are formed by hydrogen bonding of the backbone to form a spiral shape (refer to figure on the right). The β pleated sheet is a structure that forms with the backbone bending over itself to form the hydrogen bonds (as displayed in the figure to the left). The hydrogen bonds are between the amide hydrogen and carbonyl oxygen of the peptide bond. There exists anti-parallel β pleated sheets and parallel β pleated sheets where the stability of the hydrogen bonds is stronger in the anti-parallel β sheet as it hydrogen bonds with the ideal 180 degree angle compared to the slanted hydrogen bonds formed by parallel sheets.
The first Thai 7-Eleven opened on 1 June 1989 on Patpong Road in Bangkok. The chain consists of both company-owned (45%) and franchised shops (55%). CP All, a listed subsidiary of Charoen Pokphand, is the 7-Eleven owner and franchisor in Thailand; Charoen Pokphand received the franchise rights for Thailand in 1988. As of 2022, CP All has a total of 13,838 stores in Thailand, an increase from 12,432 in 2020. In 2018, 7-Eleven generated 335,532 million baht in income for CP. 7-Eleven holds a 70% market share in the convenience store category, opposed by some 7,000 other convenience stores (e.g., FamilyMart) and 400,000 "mom and pop" shops. Thailand has the second largest number of 7-Eleven stores after Japan. In an effort to reduce plastic pollution the parent company of 7-Eleven stores in Thailand, CP All, announced their intent in November 2018 to reduce and eventually end the use of single-use plastic bags. As of January 2020, 7-Eleven—along with 42 other Thai retailers—will stop giving single-use plastic bags to customers. However, the use of plastic bags is still prevalent in many shops throughout the country, as are plastic straws.
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.